SCHEMBL8735564

SCHEMBL8735564

c1ccc(-c2cc(-c3ccc(-c4c5ccccc5c(-c5ccccc5)c5ccccc45)cn3)cc(-n3c4ccccc4c4ccncc43)c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CDK4 P11802 1/20 0.33
CDK6 Q00534 1/20 0.33
DYRK1A Q13627 2/20 0.32
GSK3B P49841 1/20 0.32
KCNH2 Q12809 1/20 0.32
MAPK10 P53779 1/20 0.32
MAPT P10636 2/20 0.32
CYP11B1 P15538 3/20 0.32
CYP11B2 P19099 3/20 0.32
CYP19A1 P11511 1/20 0.32
P2RX3 P56373 1/20 0.31
P2RX2 Q9UBL9 1/20 0.31
DHODH Q02127 1/20 0.31
ALOX5 P09917 1/20 0.31
MEN1 O00255 1/20 0.31
HSP90AA1 P07900 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9921665 0.88 CYP11B1 (0.38) MAPK10CYP11B1CYP11B2CYP19A1DHODH
SCHEMBL12919317 0.88 KDM4E (0.39) KDM4EATML3MBTL1CDK4CDK6
SCHEMBL9922137 0.81 KDM4E (0.39) KDM4EATML3MBTL1CDK4CDK6
SCHEMBL19271526 0.81 KDM4E (0.49) KDM4EATML3MBTL1CDK4CDK6
SCHEMBL2758575 0.81 KDM4E (0.49) KDM4EATML3MBTL1CDK4CDK6
SCHEMBL12919310 0.80 MAOA (0.36) KDM4EATML3MBTL1CDK4CDK6
SCHEMBL15945595 0.79 KDM4E (0.45) KDM4EATML3MBTL1CDK4CDK6
SCHEMBL15945602 0.79 KDM4E (0.41) KDM4EATML3MBTL1CDK4CDK6
SCHEMBL21481441 0.79 KDM4E (0.41) KDM4EATML3MBTL1CDK4CDK6
SCHEMBL15945590 0.79 KDM4E (0.45) KDM4EATML3MBTL1CDK4CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9755152-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2017-09-05 US disclosed
US-9755152-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2017-09-05 US disclosed
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-06-04 US disclosed
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-06-04 US disclosed
US-8927119-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2015-01-06 US disclosed
US-8927119-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2015-01-06 US disclosed
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2012-05-24 US disclosed
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE SLCO2B1, PNPO, SLCO2A1 KDM4E 1576/4885ATM 2631/4885L3MBTL1 3679/4885
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE SLCO2B1, PNPO, SLCO2A1 KDM4E 1576/4885ATM 2631/4885L3MBTL1 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.